Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 北京键凯科技股份有限公司（以下简称"公司"）预计2025年年度实现营业收入约31,500万元，与上年 同期相比，将增加8,790.32万元，同比增加38.71%。 ● 预计2025年年度实现归属于母公司所有者的净利润为6,000万元至 6,600万元，与上年同期相比，将增 加3,016.22万元至3,616.22万元，同比增加101.09%至121.20%。 证券代码：688356 证券简称：键凯科技 公告编号：2026-003 北京键凯科技股份有限公司2025年年度业绩预告 二、上年同期业绩情况和财务状况 （一）营业收入: 22,709.68 万元。 ● 预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为4,500万元至5,000万元，与 上年同期相比，将增加2,552.02万元至3,052.02万元，同比增加131.01%至156.68%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二） ...

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]

2025年度，公司营业收入预计同比增长38.71%，归属于母公司所有者的净利润预计同比增加101.09%至 121.20%，归属于母公司所有者的扣除非经常性损益的净利润预计同比增加131.01%至156.68%，主要得 益于下游海外新药客户产品上市后销售放量带来的订单收入增长以及对应的利润增长。 键凯科技(688356.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司所有者的净利润为 6,000万元至6,600万元，与上年同期相比，将增加3,016.22万元至3,616.22万元，同比增加101.09%至 121.20%。 ...

(本文来自第一财经) 键凯科技公告，预计2025年年度实现营业收入约31500万元，与上年同期相比，将增加8790.32万元，同 比增加38.71%。预计2025年年度实现归属于母公司所有者的净利润为6000万元至6600万元，与上年同 期相比，将增加3016.22万元至3616.22万元，同比增加101.09%至121.20%。 ...

每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ （记者 曾健辉） 每经AI快讯，键凯科技1月22日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为6000万元至6600万元，与上年同期相比，将增加3016.22万元至3616.22万元，同比增加 101.09%~121.2%。业绩变动主要原因是，2025年度，公司营业收入预计同比增长38.71%，归属于母公 司所有者的净利润预计同比增加101.09%至121.2%，归属于母公司所有者的扣除非经常性损益的净利润 预计同比增加131.01%至156.68%，主要得益于下游海外新药客户产品上市后销售放量带来的订单收入 增长以及对应的利润增长。 ...

证券代码：688356 证券简称：键凯科技 公告编号：2026-003 北京键凯科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 1 北京键凯科技股份有限公司（以下简称"公司"）预计 2025 年年度实现 营业收入约 31,500 万元，与上年同期相比，将增加 8,790.32 万元，同 比增加 38.71%。 预计 2025 年年度实现归属于母公司所有者的净利润为 6,000 万元至 6,600 万元，与上年同期相比，将增加 3,016.22 万元至 3,616.22 万元， 同比增加 101.09%至 121.20%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利 润为 4,500 万元至 5,000 万元，与上年同期相比，将增加 2,552.02 万 元至 3,052.02 万元，同比增加 131.01%至 156.68%。 2.预计 2025 年年度实现归属于母公司所有者的净利润为 6,000 ...

2025年度，公司营业收入预计同比增长38.71%，归属于母公司所有者的净利润预计同比增加101.09%至 121.20%，归属于母公司所有者的扣除非经常性损益的净利润预计同比增加131.01%至156.68%，主要得 益于下游海外新药客户产品上市后销售放量带来的订单收入增长以及对应的利润增长。 格隆汇1月22日丨键凯科技(688356.SH)公布，公司预计2025年年度实现营业收入约31,500万元，同比增 加38.71%。预计2025年年度实现归属于母公司所有者的净利润为6,000万元至6,600万元，同比增加 101.09%至121.20%。预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为4,500万 元至5,000万元，同比增加131.01%至156.68%。 ...

键凯科技1月22日公告，北京键凯科技股份有限公司预计2025年年度实现营业收入约31,500万元，与上 年同期相比，将增加8,790.32万元，同比增加38.71%。预计2025年年度实现归属于母公司所有者的净利 润为6,000万元至6,600万元，与上年同期相比，将增加3,016.22万元至3,616.22万元，同比增加101.09% 至121.20%。 ...

人民财讯1月22日电，键凯科技(688356)1月22日公告，公司预计2025年度实现归母净利润6000万元至 6600万元，同比增长101.09%至121.2%。本期业绩增长主要得益于下游海外新药客户产品上市后销售放 量带来的订单收入增长以及对应的利润增长。 ...